GSK2110183

DRUG3 trials

Sponsors

GlaxoSmithKline, Novartis

Conditions

CancerLangerhans Cell HistiocytosisMultiple Myeloma

Phase 1

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

CompletedNCT01428492

NovartisMultiple Myeloma

Start: 2011-12-31End: 2015-10-31Updated: 2018-08-08

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

CompletedNCT01476137

GlaxoSmithKlineCancer

Start: 2011-10-26End: 2013-03-12Updated: 2017-11-13

Phase 2

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

CompletedNCT01395004

GlaxoSmithKlineLangerhans Cell Histiocytosis

Start: 2011-11-30End: 2013-11-30Updated: 2020-09-09

Related Papers

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Blood2015-12-032 citations